Cj. Langer et al., INTRAPERITONEAL CISPLATIN AND ETOPOSIDE IN PERITONEAL MESOTHELIOMA - FAVORABLE OUTCOME WITH A MULTIMODALITY APPROACH, Cancer chemotherapy and pharmacology, 32(3), 1993, pp. 204-208
Ten patients with histologically documented peritoneal mesothelioma we
re treated with intraperitoneal cisplatin 200 mg/m2, Sodium thiosulfat
e rescue and etoposide 65 - 290 mg/m2 every 4 weeks for a maximum of s
ix cycles. All had epithelial or mixed epithelial-fibrous histology. T
oxicity was tolerable, with 50% sustaining grade 3 or 4 granulocytopen
ia. There was one episode of neutropenic fever. Grade 2 peripheral neu
ropathy occurred in one patient, grade 1 in five patients. Complete re
mission occurred in one of five patients with measurable disease. Medi
an survival for patients whose tumors were surgically debulked to <2 c
m residua prior to treatment was 22 months, while it was 5 months for
those with measurable, surgically inaccessible disease (P = 0.0731 by
Cox regression proportional hazard model). These data suggest that pat
ients who present with resectable disease may benefit from an aggressi
ve adjuvant approach. This possibility warrants prospective testing in
a randomized clinical trial.